Alice Mims

Oct 12, 2024 | tandfonline.com | Jonathan E. Brammer |Alice Mims |Sarah Wall |Jean Caputo

FDA approved agents for the treatment of chronic GVHD including ruxolitinib and belumosudil are effective steroid-sparing agents, with overall response rates (ORR) of 76% and 65% respectively. Ruxolitinib and belumosudil are well tolerated with different primary targets. Little data is available on the use of combination ruxolitinib and belumosudil.

Oct 4, 2024 | nature.com | Maarten WJ Fornerod |Deedra Nicolet |Benjamin Kelly |Krzysztof Mrózek |Jean F. Kloppers |Anne-Cecilia van Marle | +21 more

AbstractGenomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the exomes and transcriptomes of 100 patients with AML with genomically confirmed African ancestry (Black; Alliance) and compared their somatic mutation frequencies with those of 323 self-reported white patients with AML, 55% of whom had genomically confirmed European ancestry (white; BeatAML).